Results 251 to 260 of about 7,676,849 (387)

Cytomegalovirus infection is common in prostate cancer and antiviral therapies inhibit progression in disease models

Molecular Oncology, EarlyView.
Human cytomegalovirus infection is common in normal prostate epithelium, prostate tumor tissue, and prostate cancer cell lines. CMV promotes cell survival, proliferation, and androgen receptor signaling. Anti‐CMV pharmaceutical compounds in clinical use inhibited cell expansion in prostate cancer models in vitro and in vivo, motivating investigation ...
Johanna Classon, Moa Stenudd, Margherita Zamboni, Kanar Alkass, Carl‐Johan Eriksson, Lars Pedersen, Alrik Schörling, Anna Thoss, Anders Bergh, Pernilla Wikström, Hans‐Olov Adami, Henrik Toft Sørensen, Henrik Druid, Jonas Frisén   +13 more
wiley   +1 more source

Voices that matter: The impact of patient-reported outcome measures on clinical decision-making. [PDF]

World J Methodol
Jeyaraman N, Jeyaraman M, Ramasubramanian S, Balaji S, Muthu S.   +4 more
europepmc   +1 more source

PCN32 INSTRUMENTS TO MEASURE PATIENT-REPORTED OUTCOMES AND PERCEPTIONS OF CANCER-RELATED FATIGUE: A REVIEW OF THE LITERATURE

, 2004
Eva Baró, MJ Herdman, JA Gasquet, Judit Sánchez   +3 more
openalex   +1 more source

Endoglin mediates the tumor‐ and metastasis‐promoting traits of stromal myofibroblasts in human breast carcinomas

Molecular Oncology, EarlyView.
Carcinoma‐associated fibroblasts (CAFs) in tumors influence cancer progression. We identified endoglin (ENG) as a key factor in TGF‐β signaling in myofibroblastic CAFs (myCAFs), linked to poor breast cancer outcomes. Inhibiting ENG on myCAFs suppressed the TGF‐β‐Smad2/3 pathway, reducing primary tumor growth and metastasis.
Shoki Okubo, Yoshihiro Mezawa, Zixu Wang, Ahmet Acar, Yasuhiko Ito, Atsushi Takano, Yohei Miyagi, Tomoyuki Yokose, Toshinari Yamashita, Yataro Daigo, Takuya Shirakihara, Akira Orimo   +11 more
wiley   +1 more source

Assessing patient reported outcome measures: A practical guide for gastroenterologists [PDF]

, 2014
Bombardier C, Devlin NJ, Deyo RA, Domino G, Drossman DA, Masachs M, Mouzas IA, Muller S, Murphy KaCD, Nightingale F, Spaccavento S, Vandenberghe A, Verissimo R   +12 more
core   +1 more source

Meaningful differences in patient-reported outcome measurement scores in liver disease. [PDF]

Hepatol Commun
Desai AP, Orman ES, Aridi TG, Stump T, Nephew L, Ghabril MS, Fallon M, Chalasani N, Monahan P.   +8 more
europepmc   +1 more source

PGI11 PSYCHOMETRIC VALIDATION OF TWO GASTROINTESTINAL (GI)-SPECIFIC PATIENT-REPORTED OUTCOME (PRO) INSTRUMENTS IN RENAL TRANSPLANT PATIENTS WITH AND WITHOUT GI COMPLICATIONS

, 2004
Leah Kleinman, Udo Bahner, Richard L. M. Faull, R Walker, Ram Prasad, Patrice Max Ambuehl, Gerardo Machnicki, MK Margolis   +7 more
openalex   +1 more source

Patient-reported outcome after carpal tunnel release for advanced disease [PDF]

, 2005
E.F. Shaw Wilgis
openalex   +1 more source

Beyond cytotoxic T cells: reprogrammed regulatory T cells help facilitate response to dual checkpoint blockade

Molecular Oncology, EarlyView.
Rolig, Peng, and colleagues have shed new light on how dual blockade of PD1 and LAG3 enhances antitumor immunity. They found that response to immunotherapy with anti‐PD1 + anti‐LAG3 was associated with reprogramming of canonically suppressive CD4+ regulatory T cells to an inflammatory state.
Tullia C. Bruno, Anthony R. Cillo
wiley   +1 more source

Correction: Patient‑reported outcome (PRO) instruments used in patients undergoing adoptive cell therapy (ACT) for the treatment of cancer: a systematic review

Systematic Reviews
Sally Taylor, Kate Law, Jake Coomber‑Moore, Michelle Davies, Fiona Thistlethwaite, Mel Calvert, Olalekan Aiyegbusi, Janelle Yorke   +7 more
doaj   +1 more source